Global Edaravone Injection Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Edaravone Injection Market Research Report 2024
Edaravone, sold as under the brand names Radicava and Radicut, is an intravenous medication used to help with recovery following a stroke[1] and to treat amyotrophic lateral sclerosis (ALS).
According to Mr Accuracy reports new survey, global Edaravone Injection market is projected to reach US$ 496 million in 2029, increasing from US$ 246 million in 2022, with the CAGR of 10.0% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Edaravone Injection market research.
The Radicava market is driven by the need for effective treatments for amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease. Radicava, containing edaravone, is an intravenous medication that has been shown to slow the decline in physical function in ALS patients. The drug's approval and positive clinical outcomes have led to its increasing adoption in ALS management. However, challenges include the high cost of the medication, the need for ongoing treatment, and access barriers in certain regions. Overcoming these challenges through affordability measures, patient support programs, and continued research to better understand and treat ALS will be crucial for the sustained growth of the Radicava market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Edaravone Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Mitsubishi Tanabe Pharma
Segment by Type
20ml
100ml
Hospital
Pharmacy
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Edaravone Injection report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Edaravone Injection market is projected to reach US$ 496 million in 2029, increasing from US$ 246 million in 2022, with the CAGR of 10.0% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Edaravone Injection market research.
The Radicava market is driven by the need for effective treatments for amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease. Radicava, containing edaravone, is an intravenous medication that has been shown to slow the decline in physical function in ALS patients. The drug's approval and positive clinical outcomes have led to its increasing adoption in ALS management. However, challenges include the high cost of the medication, the need for ongoing treatment, and access barriers in certain regions. Overcoming these challenges through affordability measures, patient support programs, and continued research to better understand and treat ALS will be crucial for the sustained growth of the Radicava market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Edaravone Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Mitsubishi Tanabe Pharma
Segment by Type
20ml
100ml
Segment by Application
Hospital
Pharmacy
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Edaravone Injection report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices